Meeting NewsVideo

VIDEO: Crizanlizumab may reduce hospitalization in sickle cell disease

ORLANDO — Julie Kanter, MD, from the division of hematology-oncology at the University of Alabama-Birmingham, discussed the first-ever targeted FDA-approved drug for sickle cell disease, crizanlizumab, in a video at the ASH Annual Meeting and Exposition.

Kanter also discussed her post-hoc analysis of the SUSTAIN study, which demonstrated patients who received crizanlizumab were hospitalized less overall than those who received placebo.

“These were not statistically significant, but very much numerically significant in that the decrease in hospitalizations was around 40%. So, very exciting data,” she said.

Disclosure: Kanter reports consulting for Bluebird Bio Crown, GLG, Guidepoint Global, Imara, Jeffries, Novartis; research funding from CDC, HRSA and NHLBI; honoraria from American Society of Hematology, Axis Medical Education, Medscape, Peerview, Pfizer, Rockpointe and Terumo; being on advisory or steering committees for AstraZeneca, Editas, Modus, NHLBI Sickle Cell Disease Advisory Committee, Novartis, Sangamon and SCDAA Medical and Research Advisory Board.

ORLANDO — Julie Kanter, MD, from the division of hematology-oncology at the University of Alabama-Birmingham, discussed the first-ever targeted FDA-approved drug for sickle cell disease, crizanlizumab, in a video at the ASH Annual Meeting and Exposition.

Kanter also discussed her post-hoc analysis of the SUSTAIN study, which demonstrated patients who received crizanlizumab were hospitalized less overall than those who received placebo.

“These were not statistically significant, but very much numerically significant in that the decrease in hospitalizations was around 40%. So, very exciting data,” she said.

Disclosure: Kanter reports consulting for Bluebird Bio Crown, GLG, Guidepoint Global, Imara, Jeffries, Novartis; research funding from CDC, HRSA and NHLBI; honoraria from American Society of Hematology, Axis Medical Education, Medscape, Peerview, Pfizer, Rockpointe and Terumo; being on advisory or steering committees for AstraZeneca, Editas, Modus, NHLBI Sickle Cell Disease Advisory Committee, Novartis, Sangamon and SCDAA Medical and Research Advisory Board.

    See more from Discoveries from ASH: Benign Hematology